Form 4: HealthEquity EVP Sells Shares Under 10b5-1 Plan

HealthEquity's EVP, Chief Commercial Officer, Michael Henry Fiore, reported the sale of 1,781 shares of common stock and disposition of 1,649 shares for tax withholding purposes.

Summary

• Michael Henry Fiore, EVP, Chief Commercial Officer of HealthEquity, Inc. (HQY), reported transactions involving the company's common stock.
• On October 6, 2025, Fiore disposed of 1,649 shares of common stock at a price of $88.5674 per share, likely for tax withholding related to vesting.
• Following this disposition, Fiore beneficially owned 51,576 shares directly.
• On October 7, 2025, Fiore sold 1,781 shares of common stock at a price of $88.21 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2024.
• After these transactions, Fiore directly beneficially owns 49,795 shares of HealthEquity common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including a planned sale under a 10b5-1 plan and a disposition for tax withholding. These are generally neutral events and do not indicate significant positive or negative sentiment regarding the company's immediate prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive transaction.

Negatives

• A reduction in insider ownership, though minor and planned, could be perceived as a slight negative by some investors.

Future Outlook

NA

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2024.

Industry Context

This is a routine insider transaction report for an executive at HealthEquity, a company in the health savings account (HSA) and consumer-directed benefits industry. Such planned sales are common for executives managing their personal finances and diversifying their portfolios.

Stakeholder Impact

• Shareholders: Minor impact. A planned insider sale is generally not a strong signal of future performance, but it does slightly reduce insider ownership.
• Employees: No direct impact.
• Customers: No direct impact.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider stock sale and a disposition for tax purposes. Such transactions, especially when executed under a Rule 10b5-1 plan, are typically for personal financial management and do not inherently signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

HealthEquity, HQY, Michael Fiore, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Common Stock